A01

Identification and characterization of molecular vulnerabilities in SCLC

In A01, C. Reinhardt and T. Wunderlich will generate a versatile in vivo platform based on existing autochthonous mouse models of SCLC, to address fundamental questions in SCLC biology and treatment response. Especially the hypothesis that SCLCs display enhanced sensitivity against cell cycle checkpoint-abrogating therapeutic interventions will be analyzed. Moreover, the team will perform in vivo insertional mutagenesis screens to search for mediators of resistance against chemo- and chemo-immunetherapy.

Principal Investigators

Univ. Prof. Dr. med. H. Christian Reinhardt SFB1399
Univ. Prof. Dr. med. H. Christian Reinhardt

Professor for Clinical and Molecular Oncology (W2) and attending physician (Oberarzt)

University Hospital of Cologne

Department I for Internal Medicine

Curriculum Vitae (CV)

PD Dr. rer. nat. Thomas Wunderlich SFB1399
PD Dr. rer. nat. Thomas Wunderlich

Junior Research Group Leader

Max Planck Institute for Metabolism Research

Curriculum Vitae (CV)

Related Publications

  • Publications will follow here…
  • Publications will follow here…
  • Publications will follow here…
A01